News From ASH
The American Society of Hematology (ASH) is the world’s largest professional society of hematologists dedicated to furthering the understanding, treatment, and prevention of disorders affecting the blood.
The Annual ASH Conference was held in San Francisco December 6-9, 2014, and included over 18,000 doctors and PHD’s, and representatives from over 300 pharmaceutical, diagnostic, and medical companies.
Novel Combinations of New and Existing Therapies Yield Promising Results for Leukemia Patients with poor Prognoses
Dec 07, 2014
read more..
Targeted Therapy Effective in Elderly Patients with Philadelphia-Positive Acute Lymphocytic Leukemia
December 7, 2014
read more..
Novel Strategies Direct Immune System to Attack Recurrent, Hard-To-Treat Blood Cancers
Dec 07, 2014
read more..
Advances in Lymphoma and Multiple Myeloma Treatment Seek to Improve Outcomes for Patients with Hard-To-Treat Disease
Dec 07, 2014
read more..
Brentuximab Vedotin Prolongs Post-Transplant Survival in Hard-to-Treat Lymphoma Patients in
Phase III Study
December 7, 2014
read more..
Carfilzomib Represents Potent, Effective Addition to Standard Multiple Myeloma Therapy in Phase III Study
December 6, 2014
read more..
Investigational Antibody Demonstrates Efficacy, Safety for Patients with Aggressive Multiple Myeloma in Phase I Study
December 7, 2014
read more..
More News from ASH 2014:
Breast Cancer Vaccine Shows Promising Results In Small Trial
http://www.iflscience.com/health-and-medicine/breast-cancer-vaccine-trial-has-promising-results
New Multiple Myeloma Treatments on the Horizon
http://www.myelomabeacon.com/news/2014/12/05/ash-2014-multiple-myeloma-new-treatments-preview/
PD-1 Inhibitors shine at Ash conference
http://www.pmlive.com/pharma_news/pd-1_inhibitors_shine_at_ash_conference_622370
PD-1 Blockade Arrives in Hematologic Cancer
http://www.medscape.com/viewarticle/836076
Brentuximab Vedotin Delivers Unprecedented Post-Transplant PFS Benefit in Relapsed Hodgkin Lymphoma
http://www.onclive.com/conference-coverage/ASH-2014/Brentuximab-Vedotin-Delivers-Unprecedented-Post-Transplant–PFS-Benefit-in-Relapsed-Hodgkin-Lymphoma
Nivolumab Scores in Tough-To-Treat Hodgkin’s Lymphoma
http://www.medpagetoday.com/MeetingCoverage/ASHHematology/48968
Watch the Best of ASH from ASH TV
http://www.hematology.org/Annual-Meeting/2361.aspx